Back to top
more

Allergan plc (AGN)

(Delayed Data from NYSE)

$145.81 USD

145.81
1,518,334

+1.56 (1.08%)

Updated May 3, 2019 04:01 PM ET

After-Market: $145.88 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acorda's (ACOR) MS Drug Patents Invalidated, Shares Plunge

by Zacks Equity Research

Acorda Therapeutics, Inc.???s (ACOR) shares were down almost 21.5% after the U.S. District Court for the District of Delaware invalidated four patents of its key multiple sclerosis drug, Ampyra.

    Why Equal Weighted Mutual Funds Scoring Over Index Funds

    by Zacks Equity Research

    Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.

      Allergan Acne Candidate Meets Endpoints in Phase III Studies

      by Zacks Equity Research

      Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

        Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

        by Zacks Equity Research

        Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

          Teva Pharma Denies Rumors of Global Workforce Reduction

          by Zacks Equity Research

          According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.

            AstraZeneca Stock Rising in '17: What's Working in its Favor?

            by Zacks Equity Research

            Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.

              Allergan's Restasis Now Available in Multidose Bottle in U.S.

              by Zacks Equity Research

              Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

                Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

                by Zacks Equity Research

                Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

                  by Arpita Dutt

                  Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

                    Allergan (AGN) and Editas Tie Up to Treat Eye Diseases

                    by Zacks Equity Research

                    Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.

                      Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise

                      by Zacks Equity Research

                      U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.

                        Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction

                        by Zacks Equity Research

                        Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.

                          Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release?

                          by Zacks Equity Research

                          Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.

                            Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

                            by Zacks Equity Research

                            Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

                              Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted

                              by Zacks Equity Research

                              Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents

                                The Zacks Analyst Blog Highlights: IBM, Allergan, Chubb, DISH Network and HP

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: IBM, Allergan, Chubb, DISH Network and HP

                                  Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

                                  by Zacks Equity Research

                                  Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

                                    Tracey Ryniec headshot

                                    Where Are the Best Buying Opportunities in Stocks Right Now?

                                    by Tracey Ryniec

                                    With stocks hitting new record highs, you might think there???s nothing left to buy. But some of the biggest money managers beg to differ.

                                      The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson

                                        Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

                                        by Zacks Equity Research

                                        Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

                                          Parth Panchal headshot

                                          Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%

                                          by Parth Panchal

                                          Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.

                                            Mark Vickery headshot

                                            Markets Climb Amid Solid Q4 Earnings

                                            by Mark Vickery

                                            Market futures are very positive this morning, and continue to climb 20 minutes before the opening bell sounds.

                                              Kinjel Shah headshot

                                              Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

                                              by Kinjel Shah

                                              Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

                                                Allergan (AGN) Beats Q4 Earnings & Sales; Shares Up

                                                by Zacks Equity Research

                                                Allergan???s fourth-quarter earnings of $3.90 per share were above our consensus estimate of $3.79 per share.

                                                  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

                                                  by Zacks Equity Research

                                                  How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?